This website uses cookies to enhance your browsing experience, analyze our traffic, and optimize our advertising efficacy as described in Quectel Cookies Policy. We also share information about your use of our site with our carefully-selected advertising and analytics third-parties to achieve the purposes set out in our Cookies Policy. To see what cookies we serve and set your preferences, please click the Find Out More link. By continuing your visit on our website, you consent to our use of cookies in accordance with Quectel Cookies Policy. Find Out More
Accept
Home > >About us > Company Profile < Back

3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient.

 

3DMed set the standard of innovation in automated molecular diagnostics and artificial intelligence (AI) to help physicians leverage genetic information to tailor treatment to individual patients.

 

3DMed clinical laboratory is accredited by College of American Pathologists (CAP) and certified by Clinical Laboratory Improvement Amendments (CLIA) to provide clinical testing in various disease areas. CAP CLIA About 3DMed

 

In 2018, 3DMed introduced an AI-based cancer genome data interpretation system, the ANDiS Genome Insight. In late 2019, 3DMed launched the world’s first fully closed automated NGS library-prep system, the ANDiS 400. 3DMed aspires to be a game changer by offering a diverse pipeline of automated molecular diagnostics.

 

Soon after the coronavirus 2019 (COVID-2019) outbreak, 3DMed responded rapidly by developing a series of RT-qPCR-based tests (the ANDiS SARS-CoV-2 Detection Kit and the ANDiS SARS-CoV-2 & Influenza A/B Detection Kit) for qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens collected from individuals who meet the CDC criteria for SARS-CoV-2 testing.